NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1 ER Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Breast Cancer
    Breast
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    1. 1) Patients must be premenopausal (evidence of functioning ovaries) at the time of preentry
    2. 2) Patients may have ipsilateral or contralateral synchronous breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy
    3. 3) Patients may have multicentric or multifocal breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy

You may not be eligible for this study if the following are true:

    1. 1) Definitive clinical or radiologic evidence of metastatic disease
    2. 2) pT4 tumors, including inflammatory breast cancer
    3. 3) History of ipsilateral or contralateral invasive breast cancer



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.